Trial · NCT05214794
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24 | Nemolizumab | -9.5 | Full Range -13 to -6 | scores on scale | |
| Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52 | Nemolizumab | -10.0 | Full Range -14 to -7 | scores on scale | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24 | Nemolizumab | 0.000 | Full Range -0.13 to 0.38 | scores on scale | |
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52 | Nemolizumab | 0.063 | Full Range -0.13 to 0.25 | scores on scale | |
| Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24 | Nemolizumab | -1.30 | Full Range -3.5 to 5.7 | percentage of actual to predicted FCV | |
| Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52 | Nemolizumab | -0.35 | Full Range -6.4 to 5.7 | percentage of actual to predicted FCV | |
| Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 24 | Nemolizumab | 0.55 | Full Range -4.5 to 8.8 | percentage of actual to predicted DLco | |
| Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52 | Nemolizumab | -3 | Full Range -6.6 to 4.4 | percentage of actual to predicted DLco | |
| Change From Baseline in Physician's Global Assessment at Week 24 | Nemolizumab | -3.30 | Full Range -5.4 to -0.9 | scores on scale | |
| Change From Baseline in Physician's Global Assessment at Week 52 | Nemolizumab | -3.10 | Full Range -6.5 to -0.6 | scores on scale | |
| Change From Baseline in Patient's Global Assessment at Week 24 | Nemolizumab | 1.30 | Full Range -1.8 to 3.8 | scores on scale | |
| Change From Baseline in Patient's Global Assessment at Week 52 | Nemolizumab | 1.70 | Full Range -0.1 to 5.1 | scores on scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05214794/results